Efficacy and Safety of Alemtuzumab in Patients With RRMS Is Durable Over 10 Years: Follow-up From the CAMMS223 Study

Authors
Category Primary study
JournalNeurology
Year 2017
This article has no abstract
Epistemonikos ID: 3720c56b5ea4902250788754047feeced53f415d
First added on: Feb 08, 2025